Tratamiento de la nefritis lúpica

Jacobson, 1997, Epidemiology and estimated population burden of selected autoinmune diseases in the United States, Clin Immunol Immunopathol, 84, 223, 10.1006/clin.1997.4412 Johnson, 1995, The prevalence and incidence of systemic lupus erythematosus in Birmingham, England. Relationship to ethnicity and country of birth, Arthritis Rheum, 38, 551, 10.1002/art.1780380415 Cervera, 1993, Systemic lupus erythematosus: clinical and immunologic patterns of disease expression in a cohort of 1000 patients, Medicine (Baltimore), 72, 113, 10.1097/00005792-199303000-00005 Cervera, 2003, Morbidity and mortality in systemic lupus erythematosus during a 10-year period: a comparison of early and late manifestations in a cohort of 1000 patients, Medicine (Baltimore), 82, 299, 10.1097/01.md.0000091181.93122.55 Golbus, 1994, Lupus nephritis. Classification, prognosis, immunopathogenesis and treatment, Rheum Dis Clin North Am, 20, 213, 10.1016/S0889-857X(21)00232-5 Howie, 2003, Powerful morphometric indicator of prognosis in lupus nephritis, QMJ, 96, 411, 10.1093/qjmed/hcg074 Mok, 2004, Predictors and outcome of renal flares after successful cyclophosphamide treatment for diffuse proliferative lupus glomerulonephritis, Arthritis Rheum, 50, 2559, 10.1002/art.20364 Churg, 1982 Weening, 2004, The classification of glomerulonephritis in systemic lupus erythematosus revisited, Kidney International, 65, 521, 10.1111/j.1523-1755.2004.00443.x Steinberg, 1991, Long-term preservation of renal function in patients with lupus nephritis receiving treatment that includes cyclophosphamide versus those treated with prednisone only, Arthritis Rheum, 34, 945, 10.1002/art.1780340803 Austin, 1986, Therapy of lupus nephritis. Controlled trial of prednisone and cytotoxic drugs, N Engl J Med, 314, 614, 10.1056/NEJM198603063141004 Boumpas, 1992, Controlled trial of pulse methylprednisolone versus two regimens of pulse cyclophosphamide in severe lupus nephritis, Lancet, 340, 741, 10.1016/0140-6736(92)92292-N Illei, 2001, Combination therapy with pulse cyclophosphamide plus pulse methylprednisolone improves long-term renal outcome without adding toxiciy in patients with lupus nephritis, Ann Intern Med, 135, 248, 10.7326/0003-4819-135-4-200108210-00009 Gourley, 1996, Methylprednisolone and cyclophosphamide, alone or in combination, in patients with lupus nephritis. A randomized, controlled trial, Ann Intern Med, 125, 549, 10.7326/0003-4819-125-7-199610010-00003 Mok, 2001, Treatment of diffuse proliferative lupus glomerulonephritis: a comparison of two cyclophosphamide-containing regimens, Am J Kidney Dis, 38, 256, 10.1053/ajkd.2001.26084 Yee, 2004, EULAR randomised controlled trial of pulse cyclophosphamide and methylprednisolone versus continous cyclophosphamide and prednisolone followed by azathioprine and prednisolone in lupus nephritis, Ann Rheum Dis, 63, 525, 10.1136/ard.2002.003574 Houssiau, 2002, Immunosuppressive therapy in lupus nephritis. The Euro-Lupus Nephritis Trial, a Randomized Trial of Low-Dose Versus High Dose Intravenous Cyclophosphamide, Arthritis Rheum, 46, 2121, 10.1002/art.10461 Houssiau, 2004, Early response to immunosuppressive therapy predicts good renal outcome in lupus nephritis, Arthritis Rheum, 50, 3934, 10.1002/art.20666 Illei, 2002, Renal flares are common in patients with severe proliferative lupus nephritis treated with pulse immunosuppressive therapy: long-term followup of a cohort of 145 patients participating in randomized controlled studies, Arthritis Rheum, 46, 995, 10.1002/art.10142 Ioannidis, 2000, Remission, relapse, and re-remission of proliferative lupus nephritis treated with cyclophosphamide, Kidney Int, 57, 258, 10.1046/j.1523-1755.2000.00832.x Berden, 1997, Lupus nephritis, Kidney Int, 52, 538, 10.1038/ki.1997.365 Cameron, 1999, Lupus nephritis, J Am Soc Nephrol, 10, 413, 10.1681/ASN.V102413 Flanc, 2004, Treatment of diffuse proliferative lupus nephritis: a metaanalysis of randomized controlled trials, Am J Kidney Dis, 43, 197, 10.1053/j.ajkd.2003.10.012 Allison, 1994, Preferential suppression of lymphocyte proliferation by mycophenolic acid and predicted long-term effects of mycophenolate mofetil in transplantation, Transplant Proc, 26, 3205 Dooley, 1999, Mycophenolate mofetil therapy in lupus nephritis: clinical observations, J Am Soc Nephrol, 10, 833, 10.1681/ASN.V104833 Gaubitz, 1999, Mycophenolate mofetil for the treatment of systemic lupus erythematosus: an open pilot trial, Lupus, 8, 731, 10.1191/096120399678840927 Kingdon, 2001, The safety and efficacy of MMF in lupus nephritis: a pilot study, Lupus, 10, 606, 10.1191/096120301682430186 Karim, 2002, Mycophenolate mofetil for systemic lupus erythematosus refactory to other immunosuppressive agents, Rheumatology (Oxford), 41, 876, 10.1093/rheumatology/41.8.876 Kapitsinou, 2004, Lupus nephritis: treatment with mycophenolate mofetil, Rheumatology (Oxford), 43, 377, 10.1093/rheumatology/keh012 Pisoni, 2005, Mycophenolate mofetil in systemic lupus erythematosus: efficacy and tolerability in 86 patients, J Rheumatol, 32, 1047 Karim, 2005, Reduction of proteinuria with mycophenolate mofetil in predominantly membranous lupus nephropathy, Rheumatology (Oxford), 44, 1317, 10.1093/rheumatology/kei019 Chan, 2000, Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis, N Engl J Med, 343, 1156, 10.1056/NEJM200010193431604 Chan, 2005, Long-term study of mycophenolate mofetil as continuous induction and maintenance treatment for diffuse proliferative lupus nephritis, J Am Soc Nephrol, 16, 1076, 10.1681/ASN.2004080686 Hu, 2002, Mycophenolate mofetil vs cyclophosphamide therapy for patients with diffuse proliferative lupus nephritis, Chin Med J (Engl), 115, 705 Ong, 2005, Randomized controlled trial of pulse intravenous cyclophosphamide versus mycophenolate mofetil in the induction therapy of proliferative lupus nephritis, Nephrology, 10, 504, 10.1111/j.1440-1797.2005.00444.x Ginzler, 2005, Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis, N Engl J Med, 353, 2219, 10.1056/NEJMoa043731 Moore, 2006, Systematic review and meta-analysis of randomized trails and cohort studies of mycophenolate mofetil in lupus nephritis, Arthritis Res Ther, 8, R182, 10.1186/ar2093 Sinclair, 2007, Mycophenolate mofetil as induction and maintenance therapy for lupus nephritis: rationale and protocol for the randomized, controlled Aspreva Lupus Management Study (ALMS), Lupus, 16, 972, 10.1177/0961203307084712 Cade, 1973, Comparison of azathioprine, prednisone and heparin, alone or combined in treating lupus nephritis, Nephron, 10, 37, 10.1159/000180176 Donadio, 1974, Further observations on the treatment of lupus nephritis with prednisone and combined prednisone and azathioprine, Arthritis Rheum, 17, 573, 10.1002/art.1780170511 Hahn, 1975, Azathioprine plus prednisone compared with prednisone alone in the treatment of systemic lupus erythematosus, Ann Intern Med, 83, 597, 10.7326/0003-4819-83-5-597 Grootscholten, 2006, Azathioprine/methylprednisolone versus cyclophosphamide in proliferative lupus nephritis. A randomized controlled trial, Kidney Int, 70, 732, 10.1038/sj.ki.5001630 Grootscholten, 2007, Treatment with cyclophosphamide delays the progression of chronic lesions more effectively than does treatment with azathioprine plus methylprednisolone in patients with proliferative lupus nephritis, Arthritis Rheum, 56, 924, 10.1002/art.22449 Ciruelo, 1996, Cumulative rate of relapse of lupus nephritis after successful treatment with cyclophosphamide, Arthritis Rheum, 39, 2028, 10.1002/art.1780391212 Mok, 2003, Treatment of severe proliferative lupus nephritis: the current state, Ann Rheum Dis, 62, 799, 10.1136/ard.62.9.799 Boumpas, 1993, Risk of sustained amenorrhea in patients with systemic lupus erythematosus receiving intermittent pulse cyclophosphamide therapy, Ann Intern Med, 119, 366, 10.7326/0003-4819-119-5-199309010-00003 Chan, 2005, Long-term outcome of patients with diffuse proliferative lupus nephritis treated with prednisolone and oral cyclophosphamide followed by azathioprine, Lupus, 14, 265, 10.1191/0961203305lu2081oa Contreras, 2004, Sequential therapies for proliferative lupus nephritis, N Engl J Med, 350, 971, 10.1056/NEJMoa031855 Contreras, 2005, Maintenance therapies for proliferative lupus nephritis: mycophenolate mofetil, azathioprine and intravenous cyclophosphamide, Lupus, 14, s33, 10.1177/096120330501400107 Dostál, 1998, Effect of 1 year cyclosporine A treatment on the activity and renal involvement of systemic lupus erythematosus: a pilot study, Lupus, 7, 29, 10.1191/096120398678919714 Caccavo, 1997, Long-term treatment of systemic lupus erythematosus with cyclosporin A, Arthritis Rheum, 40, 27, 10.1002/art.1780400106 Hallegua, 2000, Cyclosporine for lupus membranous nephritis: experience with ten patients and review of the literature, Lupus, 9, 241, 10.1191/096120300680198935 Tam, 1998, Long-term treatment of lupus nephritis with cyclosporin A, Q J Med, 91, 573, 10.1093/qjmed/91.8.573 Moroni, 2006, A randomized pilot trial comparing cyclosporine and azathioprine for maintenance therapy in diffuse lupus nephritis over four years, Clin J Am Soc Nephrol, 1, 925, 10.2215/CJN.02271205 Mok, 2006, Therapeutic options for resistant lupus nephritis, Semin Arthritis Rheum, 36, 71, 10.1016/j.semarthrit.2006.04.008 Mok, 2005, Tacrolimus for induction therapy of diffuse proliferative lupus nephritis: An open-labeled pilot study, Kidney Int, 68, 813, 10.1111/j.1523-1755.2005.00461.x Tse, 2007, A pilot study on tacrolimus treatment in membranous or quiescent lupus nephritis with proteinuria resistant to angiotensin inhibition or blockade, Lupus, 16, 46, 10.1177/0961203306073167 Buhaescu, 2007, Treament of proliferative lupus nephritis –A critical approach, Semin Arthritis Rheum, 36, 224, 10.1016/j.semarthrit.2006.09.002 Remer, 2001, Benefits of leflunomide in systemic lupus erythematosus: a pilot observational study, Lupus, 10, 480, 10.1191/096120301678416033 Tam, 2004, Double-blind, randomized, placebo-controlled pilot study of leflunomide in systemic lupus erythematosus, Lupus, 13, 601, 10.1191/0961203304lu1067sr Cui, 2005, Treatment of proliferative lupus nephritis with leflunomide and steroid: a prospective multicenter controlled clinical trial, Zhonghua Nei Ke Za Zhi, 44, 672 Tam, 2006, Satety and efficacy of leflunomide in the treatment of lupus nephritis refractory or intolerant to traditional immunosuppressive therapy: an open trial, Ann Rheum Dis, 65, 417, 10.1136/ard.2005.044248 Ginzler, 2005, Newer therapeutic approaches for systemic lupus erythematosus, Rheum Dis Clin N Am, 31, 315, 10.1016/j.rdc.2005.01.003 Furie, 2006, Abetimus sodium (Riquent) for the prevention of nephritis flares in patients with systemic lupus erythematosus, Rheum Dis Clin North Am, 32, 149, 10.1016/j.rdc.2005.11.001 Alarcón-Segovia, 2003, LJP 394 for the prevention of renal flare in patients with systemic lupus erythematosus, Arthritis Rheum, 48, 442, 10.1002/art.10763 Cardiel, 2005, Abetimus sodium: a new therapy for delaying the time to, and reducing the incidence of, renal flare and/or major systemic lupus erythematosus flares in patients with systemic lupus erythematosus who have a history of renal disease, Expert Opin Investig Drugs, 14, 77, 10.1517/13543784.14.1.77 Wallace, 2004, LJP 394 (abetimus sodium, Riquent) in the management of systemic lupus erythematosus, Lupus, 13, 323, 10.1191/0961203304lu1020oa Strand, 2003, for the LJP 394 Investigator Consortium. Improvement in heal-threlated quality of life in SLE patients enrolled in a randomized clinical trial comparing LJP 394 treatment with placebo, Lupus, 12, 677, 10.1191/0961203303lu440oa Aringer, 2004, Safety and efficacy of tumor necrosis factor α blockade in systemic lupus erythematosus: An open-label study, Arthritis Rheum, 50, 3161, 10.1002/art.20576 Leandro, 2002, An open study of B lymphocyte depletion in systemic lupus erythematosus, Arthritis Rheum, 46, 2673, 10.1002/art.10541 Leandro, 2005, B-cell depletion in the treatment of patients with systemic lupus erythematosus: a longitudinal analysis of 24 patients, Rheumatology, 44, 1542, 10.1093/rheumatology/kei080 Sfikakis, 2005, Remission of proliferative lupus nephritis following B cell depletion therapy is preceded by down-regulation of the T cell costimulatory molecule CD40 ligand, Arthritis Rheum, 52, 501, 10.1002/art.20858 Vigna-Pérez, 2006, Clinical and immunological effects of rituximab in patients with lupus nephritis refractory to conventional therapy: a pilot study, Arthritis Res Ther, 8, R83, 10.1186/ar1954 Gunnarsson, 2007, Histopathologic and clinical outcome of rituximab treatment in patients with cyclophosphamide-resistant proliferative lupus nephritis, Arthritis Rheum, 56, 1263, 10.1002/art.22505 Stohl, 2007, Progressive normalization of autoantibody, immunoglobulin, and complement levels over 2.5 years of belimumab (fully human monoclonal antibody to BLyS) therapy in systemic lupus erythematosus (SLE) patients, Arthritis Rheum, 56, S210 Merrill, 2007, Safety profile of belimumab (fully human monoclonal antibody to BLyS) in patients with systemic lupus erythematosus (SLE) treated during a placebo-controlled trial and in a long-term continuation study, Arthritis Rheum, 56, S210 Petri, 2007, Novel combined response endpoint and systemic lupus erythematosus (SLE) flare index (SFI) demonstrate belimumab (fully human monoclonal antibody to BLyS) improves or stabilizes SLE disease activity and reduces flare rate over 2.5 years of therapy, Arthritis Rheum, 56, S527 Strand, 2006, for the LBSL02 Study Group Patients with active systemic lupus erythematosus (SLE) treated with belimumab improve health-related quality of life (HRQOL) in a randomized controlled trial (RCT), Arthritis Rheum, 54, S277 Toubi, 2005, High-dose intravenous immunoglobulins: an option in the treatment of systemic lupus erythematosus, Hum Immunol, 66, 395, 10.1016/j.humimm.2005.01.022 Zandman-Goddard, 2005, Intravenous immunoglobulin therapy and systemic lupus erythematosus, Clin Rev Allergy Immunol, 29, 219, 10.1385/CRIAI:29:3:219 Sherer, 2006, Intravenous immunoglobulin for immunomodulation of systemic lupus erythematosus, Autoimmun Rev, 5, 153, 10.1016/j.autrev.2005.09.002 Boletis, 1999, Intravenous immunoglobulin compared with cyclophosphamide for proliferative lupus nephritis, Lancet, 354, 569, 10.1016/S0140-6736(99)01575-5 Orbach, 2004, Intravenous immunoglobulin and the kidney - a two-edged sword, Semin Arthritis Rheum, 34, 593, 10.1016/j.semarthrit.2004.06.003 Winder, 1993, Treatment of systemic lupus erythematosus by prolonged administration of high dose intravenous immunoglobulin: report of 2 cases, J Rheumatol, 20, 495 Levy, 2000, Intravenous immunoglobulin treatment of lupus nephritis, Semin Arthritis Rheum, 29, 321, 10.1016/S0049-0172(00)80018-9 Lewis, 1992, A controlled trial of plasmapheresis therapy in severe lupus nephritis. The Lupus Nephritis Collaborative Study Group, N Engl J Med, 326, 1373, 10.1056/NEJM199205213262101 Wallace, 1998, Randomized controlled trial of pulse/synchronization cyclophosphamide/apheresis for proliferative lupus nephritis, J Clin Apher, 13, 163, 10.1002/(SICI)1098-1101(1998)13:4<163::AID-JCA4>3.0.CO;2-1 Danieli, 2002, Synchronized therapy and high-dose cyclophosphamide in proliferative lupus nephritis, J Clin Apher, 17, 72, 10.1002/jca.10020 Font, 2001, Cardiovascular risk factors and the long-term outcome of lupus nephritis, Q J Med, 94, 19, 10.1093/qjmed/94.1.19 Clark, 1998, Management of chronic renal insufficiency in lupus nephritis: Role of proteinuria, hypertension and dyslipidemia in the progression of renal disease, Lupus, 7, 649, 10.1191/096120398678920802 Tse, 2005, Angiotensin inhibition or blockade for the treatment of patients with quiescent lupus nephritis and persistent proteinuria, Lupus, 14, 947, 10.1191/0961203305lu2249oa Ettinger, 1987, Dyslipoproteinemia in systemic lupus erythematosus, Am J Med, 83, 503, 10.1016/0002-9343(87)90762-5 Haubitz, 2007, Exploring new territory: the move towards individualised treatment, Lupus, 16, 227, 10.1191/0961203306075616 Wierzbicki, 2000, Lipids, cardiovascular disease and atherosclerosis in systemic lupus erythematosus, Lupus, 9, 194, 10.1191/096120300678828235 Mok, 2007, Risk and predictors of arterial thrombosis in lupus and non-lupus primary glomerulonephritis: a comparative study, Medicine (Baltimore), 86, 203, 10.1097/md.0b013e318123f888 Schneider, 2007, Exploring new territory: considering the future, Lupus, 16, 221, 10.1177/0961203306075615